DTB podcast
Summary: From June 2023, all our podcasts will move to https://dtbbmj.podbean.com. You can continue with your subscription on your favourite podcast App. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
- Visit Website
- RSS
- Artist: BMJ Group
- Copyright: 643134
Podcasts:
In the August's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the results of an awarding research paper that assessed the impact of spending the second stage of labour either in a recumbent or upright position. Read the editorial: https://dtb.bmj.com/content/56/8/85. The editors also consider nutritional support in primary care (https://dtb.bmj.com/content/56/8/90) and discuss new licensing pathways that provide faster access to medicines (https://dtb.bmj.com/content/56/8/93).
In the August's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the results of an awarding research paper that assessed the impact of spending the second stage of labour either in a recumbent or upright position. Read the editorial: https://dtb.bmj.com/content/56/8/85. The editors also consider nutritional support in primary care (https://dtb.bmj.com/content/56/8/90) and discuss new licensing pathways that provide faster access to medicines (https://dtb.bmj.com/content/56/8/93).
In July’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of drug interactions with herbal medicines. Read the editorial: https://dtb.bmj.com/content/56/7/73. The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).
In July’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of drug interactions with herbal medicines. Read the editorial: https://dtb.bmj.com/content/56/7/73. The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).
In the June’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether a recently published large meta-analysis on the effectiveness of antidepressants tells us anything new. Read the editorial here: dtb.bmj.com/content/56/6/61. The editors also review the evidence for the combination analgesic of tramadol/dexketoprofen (dtb.bmj.com/content/56/6/66), and question the dose of paracetamol for older people (dtb.bmj.com/content/56/6/69).
In the June’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether a recently published large meta-analysis on the effectiveness of antidepressants tells us anything new. Read the editorial here: dtb.bmj.com/content/56/6/61. The editors also review the evidence for the combination analgesic of tramadol/dexketoprofen (dtb.bmj.com/content/56/6/66), and question the dose of paracetamol for older people (dtb.bmj.com/content/56/6/69).
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the evidence for pulmonary rehabilitation for COPD and highlight the need for more publicity for its benefits. Read the editorial here: http://dtb.bmj.com/content/56/5/49. The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the evidence for pulmonary rehabilitation for COPD and highlight the need for more publicity for its benefits. Read the editorial here: http://dtb.bmj.com/content/56/5/49. The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a national campaign in England that is tackling the inappropriate use of antipsychotic and antidepressant medicines in people with learning or intellectual disability. Read the article: http://dtb.bmj.com/content/56/4/37. The editors also review the evidence for a once-daily triple inhaler for maintenance treatment for adults with moderate to severe COPD (http://dtb.bmj.com/content/56/4/42), and discuss off-label use of high-dose antihistamines for chronic spontaneous urticaria in adults (http://dtb.bmj.com/content/56/4/45).
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a national campaign in England that is tackling the inappropriate use of antipsychotic and antidepressant medicines in people with learning or intellectual disability. Read the article: http://dtb.bmj.com/content/56/4/37. The editors also review the evidence for a once-daily triple inhaler for maintenance treatment for adults with moderate to severe COPD (http://dtb.bmj.com/content/56/4/42), and discuss off-label use of high-dose antihistamines for chronic spontaneous urticaria in adults (http://dtb.bmj.com/content/56/4/45).
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the difficulties in implementing clinical guidelines for the management of elevated blood pressure and the potential impact of changes in the threshold for a diagnosis of hypertension (http://dtb.bmj.com/content/56/3/25). The editors also review the evidence for dupliumab for the treatment of moderate-to-severe atopic dermatitis in adults (http://dtb.bmj.com/content/56/3/30) and discuss drug names (http://dtb.bmj.com/content/56/3/33). Read the full March 2018 issue here: http://dtb.bmj.com/content/56/3.
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the difficulties in implementing clinical guidelines for the management of elevated blood pressure and the potential impact of changes in the threshold for a diagnosis of hypertension (http://dtb.bmj.com/content/56/3/25). The editors also review the evidence for dupliumab for the treatment of moderate-to-severe atopic dermatitis in adults (http://dtb.bmj.com/content/56/3/30) and discuss drug names (http://dtb.bmj.com/content/56/3/33). Read the full March 2018 issue here: http://dtb.bmj.com/content/56/3.
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of developing patient decision aids to support the implementation of clinical guidelines (http://dtb.bmj.com/content/56/2/13). The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of developing patient decision aids to support the implementation of clinical guidelines (http://dtb.bmj.com/content/56/2/13). The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of exercise, diet and behaviour modification in the management of obesity and consider the limitations of anti-obesity drugs. http://dtb.bmj.com/content/56/1/1 The editors also review the evidence for ▼patiromer, a cation exchange polymer, that has recently been marketed for the management of hyperkalaemia - http://dtb.bmj.com/content/56/1/6 and discuss the management of gout. http://dtb.bmj.com/content/56/1/9
